Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Identify and Assess Drug Interactions with Atorvastatin in Inpatient Care

View through CrossRef
Background: Atorvastatin is a recent HMG-COA reductase inhibitor used to treat primary hypercholesterolemia, homozygous familial hypercholesterolemia, and mixed dyslipidemias. It is also taken to prevent heart disease, including strokes and heart attacks. In addition, Atorvastatin is used to lower bad cholesterol low-density lipoproteins (LDL) levels, increase good cholesterol high-density lipoprotein (HDL) levels, and lower triglycerides. It works by reducing the amount of cholesterol produced in the body, hence reducing the amount of cholesterol that may build up on the walls of arteries. Atorvastatin is long-acting, has few adverse effects, and is low in price. Nevertheless, it interacts with a wide variety of medications. These interactions may be lead to adverse drug reactions. Objective: The study aims to identify and asset atorvastatin interactions with other medicines at King Abdulaziz Hospital. Also, to prevent atorvastatin interactions in the future. Methods: The retrospective study investigated 280 electronic prescriptions inside the inpatient clinic at King Abdulaziz Hospital in Saudi Arabia between January and April 2021 to identify and asset interactions among atorvastatin and different medications. Results: Most atorvastatin interactions are category C (44.64%) and category B (41.43%). Atorvastatin had the most common interactions with esomeprazole (16.07%), clopidogrel (14.64%), and sitagliptin (12.14%). Atorvastatin had clinical interactions with medications metabolized by the cytochrome P450 3A4 )CYP3A4(. Use of atorvastatin with cyclosporine or clarithromycin increased the risk for atorvastatin toxicities such as myopathy and rhabdomyolysis. In addition, Atorvastatin decreases clopidogrel's antiplatelet effect and increases the risk of skeletal muscle toxicity of daptomycin. Conclusion: The majority of atorvastatin interactions may be avoided by adhering to best practices in clinical care and clinical pharmacology, such as avoiding complicated treatment regimens, utilizing a single pharmacy for all prescriptions, and recognizing patient risk factors. Health care professionals should use drug-drug interaction checkers such as Medscape and Micromedex, as well as a book such as the Handbook of Drug Interactions.
Title: Identify and Assess Drug Interactions with Atorvastatin in Inpatient Care
Description:
Background: Atorvastatin is a recent HMG-COA reductase inhibitor used to treat primary hypercholesterolemia, homozygous familial hypercholesterolemia, and mixed dyslipidemias.
It is also taken to prevent heart disease, including strokes and heart attacks.
In addition, Atorvastatin is used to lower bad cholesterol low-density lipoproteins (LDL) levels, increase good cholesterol high-density lipoprotein (HDL) levels, and lower triglycerides.
It works by reducing the amount of cholesterol produced in the body, hence reducing the amount of cholesterol that may build up on the walls of arteries.
Atorvastatin is long-acting, has few adverse effects, and is low in price.
Nevertheless, it interacts with a wide variety of medications.
These interactions may be lead to adverse drug reactions.
Objective: The study aims to identify and asset atorvastatin interactions with other medicines at King Abdulaziz Hospital.
Also, to prevent atorvastatin interactions in the future.
Methods: The retrospective study investigated 280 electronic prescriptions inside the inpatient clinic at King Abdulaziz Hospital in Saudi Arabia between January and April 2021 to identify and asset interactions among atorvastatin and different medications.
Results: Most atorvastatin interactions are category C (44.
64%) and category B (41.
43%).
Atorvastatin had the most common interactions with esomeprazole (16.
07%), clopidogrel (14.
64%), and sitagliptin (12.
14%).
Atorvastatin had clinical interactions with medications metabolized by the cytochrome P450 3A4 )CYP3A4(.
Use of atorvastatin with cyclosporine or clarithromycin increased the risk for atorvastatin toxicities such as myopathy and rhabdomyolysis.
 In addition, Atorvastatin decreases clopidogrel's antiplatelet effect and increases the risk of skeletal muscle toxicity of daptomycin.
Conclusion: The majority of atorvastatin interactions may be avoided by adhering to best practices in clinical care and clinical pharmacology, such as avoiding complicated treatment regimens, utilizing a single pharmacy for all prescriptions, and recognizing patient risk factors.
Health care professionals should use drug-drug interaction checkers such as Medscape and Micromedex, as well as a book such as the Handbook of Drug Interactions.

Related Results

Profil Klinik dan Farmakoterapi Anti-Dislipidemia Diabetes di Rumah Sakit Gunawan Mangunkusumo Ambarawa
Profil Klinik dan Farmakoterapi Anti-Dislipidemia Diabetes di Rumah Sakit Gunawan Mangunkusumo Ambarawa
Dyslipidemia is characterized by increased plasma TG, low HDL-c, and high LDL-c, which is commonly found in patients with diabetes mellitus (DM) and is one of the main causes of is...
e0034 Inhibition of atorvastatin on the autophagy of vascular endothelial cells
e0034 Inhibition of atorvastatin on the autophagy of vascular endothelial cells
Objective To explore the mechanism of atorvastatin's protection on vascular endothelial cells, we conducted the research of impact of atorvastatin on vascular end...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
The Effect of Cytochrome P450 and Organic Anion Transporter Polypeptide on Macrolides–Atorvastatin Drug Interaction
The Effect of Cytochrome P450 and Organic Anion Transporter Polypeptide on Macrolides–Atorvastatin Drug Interaction
Cytochrome P450 (CYP3A4) enzymes and organic anion-transporting polypeptides (OATPs) are critical in drug pharmacokinetics. Fifteen rabbits were divided into three groups: the ator...
Cost-effectiveness of statin therapy in categories of patients in the UK
Cost-effectiveness of statin therapy in categories of patients in the UK
Abstract Background Cardiovascular disease (CVD) mortality has declined steadily over the last few decades across Europe and Nor...

Back to Top